Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Tyler Robin

Concepts (217)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Radiosurgery
12
2023
298
3.710
Why?
Small Cell Lung Carcinoma
6
2023
77
2.840
Why?
Brain Neoplasms
10
2023
980
2.290
Why?
Lung Neoplasms
10
2023
2207
1.730
Why?
Uterine Cervical Neoplasms
7
2023
213
1.650
Why?
Brachytherapy
8
2023
104
1.630
Why?
Cranial Irradiation
4
2020
66
1.490
Why?
Carcinoma, Non-Small-Cell Lung
6
2023
963
1.180
Why?
Prostatic Neoplasms
4
2023
927
1.110
Why?
Prostate-Specific Antigen
2
2021
151
0.880
Why?
Radiotherapy, Adjuvant
4
2019
182
0.810
Why?
Melanoma
2
2018
651
0.750
Why?
Standard of Care
2
2021
63
0.710
Why?
Oropharyngeal Neoplasms
2
2016
39
0.630
Why?
Radiotherapy, Intensity-Modulated
2
2018
123
0.610
Why?
CTLA-4 Antigen
1
2018
78
0.610
Why?
Prostatectomy
1
2018
98
0.600
Why?
Radiation Oncology
1
2018
76
0.590
Why?
Oncologists
1
2018
31
0.590
Why?
Carcinoma, Adenosquamous
1
2017
9
0.580
Why?
Carcinoma, Mucoepidermoid
1
2017
15
0.580
Why?
Paranasal Sinus Neoplasms
1
2017
17
0.570
Why?
Carcinoma, Adenoid Cystic
1
2017
17
0.570
Why?
Nose Neoplasms
1
2017
15
0.570
Why?
Chemoradiotherapy
3
2019
187
0.570
Why?
Programmed Cell Death 1 Receptor
1
2018
193
0.550
Why?
Carcinoma, Neuroendocrine
1
2016
29
0.540
Why?
Antibodies
1
2018
374
0.530
Why?
Physician's Role
1
2018
199
0.530
Why?
Submandibular Gland
1
2015
15
0.510
Why?
Clinical Decision-Making
1
2018
273
0.500
Why?
Adenocarcinoma
2
2021
799
0.490
Why?
Protein Tyrosine Phosphatases
2
2014
147
0.490
Why?
Carcinoma, Squamous Cell
2
2017
577
0.490
Why?
Aged
18
2021
19250
0.490
Why?
Liver Neoplasms
1
2018
521
0.470
Why?
Internet
1
2018
602
0.460
Why?
Physician-Patient Relations
1
2018
465
0.450
Why?
Head and Neck Neoplasms
1
2017
425
0.420
Why?
Proto-Oncogene Protein c-fli-1
1
2012
16
0.410
Why?
RNA-Binding Protein EWS
1
2012
16
0.410
Why?
Radiotherapy Dosage
5
2023
246
0.410
Why?
Humans
43
2023
115589
0.400
Why?
Databases, Factual
6
2021
1138
0.400
Why?
Neoadjuvant Therapy
4
2018
301
0.400
Why?
Genital Neoplasms, Female
2
2023
73
0.400
Why?
Pancreatic Neoplasms
2
2017
722
0.400
Why?
Sarcoma, Ewing
1
2012
62
0.390
Why?
Neoplasm Staging
7
2021
1178
0.380
Why?
Healthcare Disparities
1
2016
485
0.370
Why?
Oncogene Proteins, Fusion
1
2012
178
0.360
Why?
Bone Neoplasms
1
2012
194
0.350
Why?
Female
26
2023
59913
0.340
Why?
Combined Modality Therapy
5
2019
1127
0.330
Why?
Neoplasms
2
2020
2118
0.320
Why?
Middle Aged
17
2021
26998
0.320
Why?
Endometrial Neoplasms
2
2021
151
0.310
Why?
Margins of Excision
2
2019
29
0.310
Why?
Hysterectomy
2
2019
118
0.300
Why?
Aged, 80 and over
7
2021
6417
0.290
Why?
Chemoradiotherapy, Adjuvant
2
2017
40
0.290
Why?
Lymph Nodes
2
2021
423
0.280
Why?
Retrospective Studies
10
2023
12608
0.280
Why?
Male
15
2023
55949
0.280
Why?
Treatment Outcome
7
2022
9159
0.280
Why?
MicroRNAs
1
2012
607
0.260
Why?
Survival Analysis
3
2018
1219
0.260
Why?
Gene Expression Regulation, Neoplastic
4
2019
1147
0.260
Why?
Neoplasm Metastasis
3
2017
526
0.260
Why?
DNA-Binding Proteins
1
2012
1316
0.250
Why?
Fiducial Markers
1
2023
8
0.220
Why?
Prostatic Neoplasms, Castration-Resistant
1
2023
40
0.220
Why?
Radiotherapy Planning, Computer-Assisted
2
2022
118
0.200
Why?
Prognosis
3
2018
3339
0.190
Why?
Follow-Up Studies
4
2018
4440
0.190
Why?
Adult
12
2021
30719
0.190
Why?
Breast Neoplasms
4
2019
1872
0.190
Why?
Lymphatic Metastasis
1
2021
276
0.180
Why?
Simulation Training
1
2021
63
0.180
Why?
Young Adult
7
2021
10470
0.180
Why?
Chemotherapy, Adjuvant
2
2018
334
0.170
Why?
Survival Rate
3
2019
1650
0.160
Why?
Aquaporin 4
1
2019
86
0.160
Why?
Carcinosarcoma
1
2018
17
0.160
Why?
Radiotherapy, Image-Guided
1
2018
30
0.160
Why?
Radiometry
1
2018
43
0.160
Why?
Necrosis
1
2019
210
0.150
Why?
India
1
2018
135
0.150
Why?
Machine Learning
1
2021
321
0.150
Why?
Thyroid Carcinoma, Anaplastic
1
2018
34
0.150
Why?
Uterine Neoplasms
1
2018
73
0.150
Why?
Biopsy
1
2021
1056
0.150
Why?
Salvage Therapy
1
2018
128
0.150
Why?
Statistics, Nonparametric
1
2018
390
0.140
Why?
Otorhinolaryngologic Surgical Procedures
1
2017
33
0.140
Why?
Antineoplastic Agents, Immunological
1
2019
154
0.140
Why?
Thymus Neoplasms
1
2017
21
0.140
Why?
Thymoma
1
2017
31
0.140
Why?
Radiotherapy, Conformal
1
2017
68
0.140
Why?
Alphapapillomavirus
1
2016
36
0.130
Why?
Patient Preference
1
2018
171
0.130
Why?
Propensity Score
1
2017
225
0.130
Why?
Database Management Systems
1
2016
50
0.130
Why?
Forecasting
1
2017
333
0.130
Why?
Randomized Controlled Trials as Topic
2
2019
1216
0.130
Why?
Organs at Risk
1
2015
30
0.130
Why?
Postoperative Care
1
2017
222
0.130
Why?
Organ Sparing Treatments
1
2015
31
0.130
Why?
Thyroid Neoplasms
1
2018
262
0.120
Why?
Patient Selection
1
2018
654
0.120
Why?
Mass Screening
1
2021
1024
0.120
Why?
Drug Administration Schedule
1
2016
724
0.120
Why?
Disease Progression
2
2018
2418
0.120
Why?
Neoplasms, Multiple Primary
1
2015
52
0.120
Why?
Kaplan-Meier Estimate
1
2016
815
0.120
Why?
Radiation Injuries
1
2015
127
0.120
Why?
Proportional Hazards Models
1
2017
1087
0.110
Why?
Multivariate Analysis
1
2017
1440
0.110
Why?
Feasibility Studies
1
2015
741
0.100
Why?
Internship and Residency
1
2021
951
0.100
Why?
United States
7
2023
12295
0.100
Why?
Genes, Tumor Suppressor
1
2012
78
0.100
Why?
Etoposide
1
2012
149
0.100
Why?
Colorectal Neoplasms
1
2018
617
0.100
Why?
Cell Line, Tumor
3
2018
2751
0.100
Why?
Longitudinal Studies
1
2018
2416
0.100
Why?
Intracellular Signaling Peptides and Proteins
1
2014
388
0.100
Why?
Doxorubicin
1
2012
290
0.090
Why?
Antineoplastic Combined Chemotherapy Protocols
1
2018
1361
0.090
Why?
Adolescent
6
2021
17890
0.090
Why?
Epithelial-Mesenchymal Transition
1
2011
167
0.090
Why?
Ovarian Neoplasms
1
2015
407
0.090
Why?
Cell Movement
1
2014
867
0.090
Why?
ErbB Receptors
2
2023
557
0.090
Why?
Transforming Growth Factor beta
1
2012
446
0.080
Why?
Nuclear Proteins
1
2014
594
0.080
Why?
Molecular Targeted Therapy
1
2012
348
0.080
Why?
Prospective Studies
2
2023
6264
0.080
Why?
Cell Survival
1
2012
1024
0.080
Why?
Antineoplastic Agents
2
2016
1893
0.080
Why?
Drug Resistance, Neoplasm
1
2012
638
0.080
Why?
Infant, Newborn
2
2017
5077
0.070
Why?
Tetradecanoylphorbol Acetate
1
2006
153
0.070
Why?
Surveys and Questionnaires
1
2018
4665
0.070
Why?
Infant
2
2017
7979
0.060
Why?
Child, Preschool
2
2017
9133
0.060
Why?
Cell Proliferation
2
2012
2194
0.060
Why?
Androgen Antagonists
1
2023
69
0.050
Why?
Child
3
2021
18489
0.050
Why?
Hormones
1
2023
132
0.050
Why?
Developing Countries
1
2023
240
0.050
Why?
Receptor Protein-Tyrosine Kinases
1
2022
225
0.050
Why?
Yersinia Infections
1
1979
4
0.040
Why?
Luminescence
1
2018
34
0.040
Why?
Gene Rearrangement
1
2018
135
0.040
Why?
Neoplasm Transplantation
1
2018
235
0.040
Why?
SEER Program
1
2018
195
0.040
Why?
Receptor, ErbB-2
1
2019
302
0.040
Why?
Predictive Value of Tests
1
2021
1805
0.030
Why?
Mice, Nude
1
2018
639
0.030
Why?
Regression Analysis
1
2019
959
0.030
Why?
Reproducibility of Results
1
2023
2800
0.030
Why?
Curriculum
1
2021
852
0.030
Why?
Liver
1
2023
1690
0.030
Why?
Clinical Competence
1
2021
912
0.030
Why?
Spectrophotometry, Ultraviolet
1
2014
75
0.030
Why?
Calorimetry
1
2014
62
0.030
Why?
Allosteric Regulation
1
2014
84
0.030
Why?
Molecular Docking Simulation
1
2014
102
0.030
Why?
Magnesium
1
2014
145
0.030
Why?
Risk Assessment
1
2022
2987
0.030
Why?
Logistic Models
1
2018
1856
0.030
Why?
Sequence Homology, Amino Acid
1
2014
352
0.030
Why?
Crystallography, X-Ray
1
2014
408
0.030
Why?
Nuclear Magnetic Resonance, Biomolecular
1
2014
238
0.030
Why?
Cohort Studies
1
2021
4944
0.020
Why?
Gene Expression Profiling
1
2018
1536
0.020
Why?
Metabolic Networks and Pathways
1
2012
168
0.020
Why?
Brain
1
2022
2373
0.020
Why?
Registries
1
2018
1770
0.020
Why?
Enzyme Inhibitors
1
2014
757
0.020
Why?
Practice Patterns, Physicians'
1
2018
1180
0.020
Why?
Amino Acid Sequence
1
2014
2000
0.020
Why?
Molecular Sequence Data
1
2014
2790
0.020
Why?
Disease Models, Animal
1
2018
3580
0.020
Why?
Protein Binding
1
2014
1917
0.020
Why?
Cell Line
1
2014
2651
0.020
Why?
Neoplastic Stem Cells
1
2011
331
0.020
Why?
Magnetic Resonance Imaging
1
2019
3071
0.020
Why?
Clinical Trials as Topic
1
2012
941
0.020
Why?
Cyclin B1
1
2006
5
0.020
Why?
Cyclin B
1
2006
13
0.020
Why?
Cyclin A
1
2006
15
0.020
Why?
Maleimides
1
2006
24
0.020
Why?
Cyclin E
1
2006
21
0.020
Why?
G2 Phase
1
2006
31
0.020
Why?
Epithelial Cells
1
2012
961
0.020
Why?
Flavonoids
1
2006
68
0.020
Why?
MAP Kinase Kinase Kinases
1
2006
68
0.020
Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2006
107
0.020
Why?
Mitogen-Activated Protein Kinase 3
1
2006
147
0.020
Why?
Risk Factors
1
2019
8697
0.020
Why?
Mitogen-Activated Protein Kinase 1
1
2006
165
0.020
Why?
Protein Kinase C
1
2006
274
0.020
Why?
Cell Division
1
2006
759
0.010
Why?
Indoles
1
2006
309
0.010
Why?
Animals
2
2018
32102
0.010
Why?
Apoptosis
1
2012
2377
0.010
Why?
Phosphorylation
1
2006
1571
0.010
Why?
Mice
1
2018
15052
0.010
Why?
Protein Kinase Inhibitors
1
2006
790
0.010
Why?
Signal Transduction
1
2012
4541
0.010
Why?
Yersinia
1
1979
2
0.010
Why?
Serotyping
1
1979
28
0.010
Why?
RNA, Messenger
1
2006
2574
0.010
Why?
New York City
1
1979
74
0.010
Why?
Species Specificity
1
1979
552
0.010
Why?
Robin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)